Antenatal magnesium sulfate and school-age outcomes

ACTOMgSO4 was a randomized multicenter trial from Australia and New Zealand, comparing magnesium sulfate with placebo given to pregnant women expected to deliver before 30 weeks gestation. Early-childhood outcomes of this trial showed a reduction in cerebral palsy with magnesium sulfate. However, when surviving infants from this trial were assessed at school age (6 – 11 years of age), no statistically significant differences were found between the magnesium and placebo groups in motor, cognitive or behavioral outcomes. Still, a mortality advantage of antenatal magnesium could not be excluded because the school-age mortality of magnesium-treated children was 14% and that of placebo-treated infants was 18% (relative risk of 0.80, 95% CI 0.62 – 1.03).

School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate. Doyle et al, 2014.